Eupraxia Pharmaceuticals (NASDAQ:EPRX) Rating Lowered to Strong Sell at Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Sunday, Wall Street Zen reports.

A number of other equities analysts have also weighed in on EPRX. Stifel Nicolaus set a $25.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. Oppenheimer reissued an “outperform” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, October 20th. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 15th. Finally, Wedbush started coverage on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. They issued an “outperform” rating and a $17.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.17.

Eupraxia Pharmaceuticals Trading Up 7.7%

Shares of EPRX stock opened at $7.42 on Friday. The stock’s fifty day moving average is $7.56 and its two-hundred day moving average is $7.26. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.00 and a current ratio of 16.00. The firm has a market capitalization of $498.92 million, a P/E ratio of -7.27 and a beta of 1.04. Eupraxia Pharmaceuticals has a fifty-two week low of $5.57 and a fifty-two week high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. Research analysts expect that Eupraxia Pharmaceuticals will post -0.90 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of EPRX. Persistent Asset Partners Ltd acquired a new stake in shares of Eupraxia Pharmaceuticals in the second quarter valued at $25,000. BlackRock Inc. acquired a new position in Eupraxia Pharmaceuticals during the 2nd quarter worth about $40,000. China Universal Asset Management Co. Ltd. boosted its holdings in Eupraxia Pharmaceuticals by 28.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock valued at $133,000 after acquiring an additional 3,500 shares during the period. AXQ Capital LP boosted its holdings in Eupraxia Pharmaceuticals by 34.2% during the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock valued at $140,000 after acquiring an additional 5,390 shares during the period. Finally, Cibc World Market Inc. purchased a new position in Eupraxia Pharmaceuticals during the 2nd quarter valued at about $1,539,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.